Approved, but cant' get it..BD
NEW YORK, (Reuters) Nov 15 - U.S. health officials have approved Roche Holding AG's long-acting erythropoiesis stimulating agent Mircera to treat anemia associated with chronic kidney disease, a Food and Drug Administration spokeswoman said Wednesday.
However, Roche has said it will not launch the drug in the United States after a Boston jury found the patents on Amgen Inc's top-selling anemia drugs to be valid. The decision effectively blocks Mircera sales in the United States.
0 comments :
Post a Comment